The development of inovirus-associated vector vaccines using phage-display technologies

Zachariah Stern, Dora C. Stylianou, and Leonios G. Kostrikis

1. Introduction

Research regarding the potential to use viruses to combat disease has been ongoing for over 100 years [1,2]. While viruses have often been considered pernicious as they co-opt a host for their own survival, often killing the host in the process, new work with viruses that can be exploited as bacteriophages but without the harmful effects has arisen [3]. These viruses, which can be easily manipulated and employed for phage display ability, are being increasingly used for a variety of potent biomedical tools [4]. These filamentous bacterial viruses, which make up the genus Inovirus in the family Inoviridae, are thread-like viruses containing single-stranded DNA genomes know as filamentous bacteriophages [5-7]. Over 50 different species of filamentous viruses are known, of which a majority can infect Gram-negative bacteria.

Although inoviruses are now being used for their phage display capabilities, these filamentous viruses have a relationship with the cell that they infect that is more similar to symbiotic non-pathogenic animal viruses than classical phages. Unlike phages, which term comes from the Greek word φάγος for destroyer, inoviruses do not kill their host and only slightly affect cell growth despite yielding titers of up to 10^{13} virions per milliliter of liquid culture. Progeny virions are assembled in the host cell's membrane where single-stranded DNA binding proteins are replaced by major capsid protein subunits before being released into the cell, resulting in opaque plaques on bacterial lawns [8,9]. Receptor organelles in the bacterial host that are encoded by transmissible plasmids facilitate the interactions between inovirus and cell [5,10]. The functional architecture of inoviruses provides the foundation for their application in vaccine-related projects since inoviruses do not cause harm.

A great number of inovirus species across the world have been isolated and characterized [5]. Despite variation by species, they have the same general physical characteristics. The virions are flexible, thin cylindrical filaments [6,7] under 10 nm in diameter and approximately 1000 nm in length (see Figure 1a for details). Most of a single virion is composed of several thousand major capsid or coat protein subunits. These surround a circular single-stranded DNA molecule. At the proximal end of the virion there are a few minor proteins which attach to the cell to initiate infection. At the distal end, there other minor proteins which are used for nucleation and assembly on the host membrane. The structures and life cycles are conserved across different species of inoviruses, resulting in similar functional applications.

Research into inovirus structure and application has been dominated by studies of Ff [11], which infect male (F^+) strains of E. coli. The most used and best understood of the Ff inoviruses are the closely related fd, f1, and M13 types (for reviews see [9–11]) for which extensive information regarding their life cycle and genetics is known. These nearly identical viruses almost perfectly share all structural motifs, including DNA and protein sequences and gene organization [12-14],
Although there are slight variations between the genomes. There are 10 genes and a non-coding intergenic region which are conserved across the Ff species [15–17] as well as DNA replication and transcriptional machinery (for a recent review see [10]). Proteins are encoded by 5 genes in the virion (g3, g6, g7, g8, and g9). Gene 8 proteins (gp8), the major coat protein, make up the vast majority of the virion, occurring in fivefold axial symmetry. Gene proteins 3 and 6 (gp3 and gp6) are located on the proximal end of the virion and are involved in stabilization and infecting the host cell. Gene proteins 7 and 9 (gp7 and gp9) are on the distal end of the virion and perform initiation assembly [18–20]. As shown in the end-to-end model in Figure 1(a), minor coat protein subunits have fivefold axial symmetry. While much research has been done into the structure of the Ff virus over the past 50 years, a conclusive structure has not been determined since the viruses cannot be crystallized. X-ray fiber diffraction studies and physiochemical measurements have revealed the five-star helical symmetry (5-fold rotation axis) of the gp8 subunit and are referred to as Class I [21–23]. However, the structure of the ssDNA and its relationship to the protein sheath is poorly understood, due to the small amount of DNA in individual virions. However, the architecture is sufficiently understood to take advantage of the structures and capabilities of the virus throughout its life cycle.

The life cycle of Ff filamentous viruses begins when an adsorption structure on the proximal end of the virus is adsorbed to the tip of the F+ specific pilus of E. coli. Following binding between the virus and the bacterial cell (for a recent review, see [10]), the major coat proteins of the
virus become associated with the inner membrane of the cell [24–26]. The virion’s circular single-stranded DNA (ssDNA) is then ejected into the cytoplasm where it is converted to a parental double-stranded replicative form (RF). Using a rolling-circle mechanism, Ff inoviruses replicate their genome. The new virion is assembled through a complex set of interactions that binds the protein subunits to the ssDNA [15–17] and embeds newly synthesized coat proteins into the bacterial membrane [27–29]. ssDNA is passed through the mature coat protein, spanning the bacterial membrane, and additional coat proteins are added on the internal edge of the membrane. Additional proteins are used to package the inovirus and release it into the cell [23,30]. Inovirus assembly on the inner membrane of the bacteria is a harmonized sequential process with both viral-encoded and host proteins playing important roles. For more extensive reviews on inovirus life cycle and replication, see reviews [10,31]. Importantly, this process, which requires both virus and host to complete, does not kill the host, making inovirus replication a sustainable process.

2. Inovirus-associated vectors

Inoviruses are useful for vaccine development because it is possible to insert random oligonucleotides into their genome. This easy genetic manipulation is the basis for inovirus display (phage display) technology [32,33]. Inoviruses that have been genetically modified to display these oligopeptides as fusion proteins on their surface are referred to as inovirus-associated vectors (IAVs). Oligopeptides can be displayed on any capsid protein (gp3, gp6, gp7, gp8, and gp9) following genetic modification. A specific oligonucleotide sequence can be inserted into the viral genome to display the desired oligopeptide as a fusion with capsid proteins gp3, gp7, gp8, or gp9. This results in the oligopeptide’s display on every copy of the target capsid protein. However, mosaic inovirus particles can be created where the specific capsid proteins display a mix of wild type and recombinant proteins with the desired oligopeptide [34]. This is done using a phagemid vector which has an extra copy of a capsid protein fused to the specific oligonucleotide. A host exposed to both the phagemid vector and a wild type capsid protein from a deficient helper phage produces mosaic IAVs displaying both wild type and oligopeptide fused capsid proteins. Work using the capsid protein gp6 has resulted only in the production of mosaic IAVs (for reviews see [35–37]) while both mosaic and non-mosaic IAVs have been produced using gp3 and gp8 (for a review see [10]) and gp7 and gp9 (for reviews see [38–40]).

As a result of the different locations, structures, and abundances of the capsid proteins in IAVs, they have differential abilities to display different oligopeptides. Figure 1(b) shows how each of the five capsid proteins of an IAV can display antigens, as have been demonstrated in published literature. The capsid protein that can display the most copies of the desired oligopeptide is gp8 due to the large amount of gp8 in each inovirus. A non-mosaic IAV can display a peptide on each of the approximately 2,700 copies of gp8. However, doing so with large peptides distorts the virus; only peptides of up to 6 amino acids can be displayed in such great quantity without affecting the structure of the inovirus. However, producing a mosaic IAV with oligopeptides on far fewer gp8 units will not cause distortion [33]. While it is theoretically possible to display an entire protein on gp3 [41], presenting on all 5 copies per virion, studies have demonstrated that at most one copy of gp3 will display the desired protein [34].

The ability of IAVs to display different random oligopeptides on their surface has many applications, and is especially useful in for vaccine development. The creation of Random Peptide Libraries (RPL), where random oligopeptides are fused to major capsid proteins (gp3 or gp8) and displayed on individual inovirus clones creating a random variety of IAVs which can be used for vaccine design via epitope mapping using monoclonal or polyclonal antibodies. These random IAVs, whose oligopeptide diversity increases with increased peptide length, can be used to identify the epitopes of specific antibodies through a process called biopanning. This allows for the isolation of IAVs displaying mimotopes which mimic the antibody discontinuous target epitope. By isolating the recombinant inoviruses bearing mimotopes, the DNA and amino acid sequence of the oligopeptides of interest can be determined. Through this breakthrough technology which was the subject matter of the Nobel Prize in Chemistry 2018 (see ‘Expert Commentary’ below), inoviruses displaying oligopeptides mimicking antigens (or specific epitopes of an antigen) can be used to vaccinate hosts thus inducing the desired antibody production. Vaccines of this sort have been developed in a variety of organisms against many different diseases (See tables 1 and 2 in [31] for a list of inovirus-based vaccines), as the introduction of the inoviruses can induce the production of specific antibodies. While there have already been various successes, this method can potentially open the door to the development of many novel vaccines and vaccine methodologies.

3. Inovirus display technology in vaccine design

IAVs have been successfully used as vaccine carriers for a variety of species and diseases across a range of vaccine studies (as shown in [31]). These vaccines have been effective against infections agents such as viral, protozoan, and worm parasites as well as non-infectious diseases including Alzheimer’s and a variety of cancers. Inovirus display technology has been used in two different ways to develop vaccines. The first method employs inovirus display technology to screen RPLs with monoclonal antibodies to determine which peptides can be used. These immunogenic peptides are used as vaccines either with carrier proteins or in their soluble forms to elicit an immune response [42–55]. The second method not only employs inoviruses for epitope mapping, but also utilizes inoviruses to serve as the carrier for the isolated immunogenic peptide [56–83]. Directly using IAVs to present the peptide has been more consistently successful in producing the production of the proper antibody than the introduction of soluble peptides. Inovirus-bound peptides (on IAVs) consistently retain their 3D structure and are more stable than soluble peptides, which do not always reflect the desired antigen epitope [84]. IAVs are structurally simple, which allows the immune system to respond to the fused peptides rather than the viral coat.
Combined with ability to display many copies of the desired peptide, IAVs are highly immunogenic, creating effective vaccines [85]. Because the inoviruses replicate in *E. coli* cultures, the production of large numbers of vaccines is cost-efficient. IAV’s structural simplicity, high immunogenicity, and economical production make them an efficient and attainable system for creating a variety of effective vaccines.

Much of the research involving inovirus-based vaccines has been to target infectious diseases in animals. Studies have shown that IAVs have been constructed to protect vaccinated animals against a variety of infectious diseases by eliciting both humoral [82] and cellular [86] immune responses. To test the efficacy of IAV vaccines against target pathogens, studies were conducted in which animals were challenged with a specific pathogen following IAV vaccination. In these studies, IAVs were shown to mitigate or prevent infection from viruses and parasites. In one study, mice were completely vaccinated against Human Respiratory Syncytial Virus (RSV) by binding a 15-mer linear epitope to gp3, which induced a humoral response [56]. Monoclonal antibodies against various viral diseases have also been successfully screened against RPLs to produce recombinant inovirus vaccines against Herpes Simplex Virus type 2 (HSV-2) using a 15-mer peptide [57] and against Neurotropic Murine Coronavirus sing a 13-mer peptide [58]. These inovirus vaccines induced humoral responses in mice, greatly reducing mortality and providing protection relative to the dose of the vaccine [57].

IAV vaccines have also been developed against fungal parasites in animals, providing both individual protection and large scale vaccination success. In 2005, Yang et al. and, in 2006, Wang et al. used inoviruses to vaccinate against systemic candidiasis, a fungal infection caused by *Candida albicans*. They used the inoviral coat protein gp8 to display a 6 amino acid peptide epitope of the fungal heat shock protein 90 to vaccinate against the infection [59,60]. Not only did vaccination lower the burden of infection, but it also increased the lifespan in the infected mice [59]. In 2004, Manoutsarian et al. used IAVs to vaccinate pigs against *Toxocra solium*, a parasitic worm which causes neurocysticercosis in humans but uses pigs as intermediate hosts. Unlike previous studies, which used a single specific peptide fused to a inovirus, four different antigenic peptides were displayed by inoviruses in a cocktail of recombinant IAVs. The induction of a cellular response completely vaccinated 1/3 of the pigs in the study and reduced the number of cysticerci in all other pigs [61]. Following the success of this study, a large-scale vaccination of 1047 pigs in Mexico was undertaken in 2008. The pigs in a natural environment were successfully immunized, reducing parasite presence in the vaccinated pigs, and providing a more cost-efficient alternative to vaccination with synthetic peptides [87]. Many additional vaccines have been developed that induced both humoral and cellular responses against parasites in animals providing partial protection against the infection and reducing infection burden. Many of these studies were done by screening monoclonal and polyclonal antibodies against large RPL (for a review of more inovirus vaccine studies see [31]).

In addition to their success against infectious diseases, inovirus display technology has been successfully used to design vaccines which prevent or mitigate the progression of non-infectious diseases. IAVs have been used to display antigen epitopes which elicit immune responses against tumors and other non-infectious diseases. An epitope of the Melanoma Antigen A1 (MAGE A1) displayed on gp8 induced a cellular immune response against the melanoma tumor in vaccinated mice. Not only did vaccination inhibit tumor growth, but it reduced mortality in the targeted mice [88]. Induction of a cellular response, decreased tumor growth, and higher survival rate was observed in mice vaccinated against murine mastocytoma P815 in a later study [89]. The highly immunogenic characteristics of inovirus display technology has also been used to activate immune responses against colorectal cancer tumors, which often evade antitumor immune responses, and to reduce tumor growth [90]. Inovirus-based vaccines have also been used against diseases such as Alzheimer’s. The same methods have been used to induce antibodies against β-amyloid plaques by displaying a specific 4 amino acid antigenic epitope on the surface of the inovirus. Multiple studies in mice using recombinant inoviruses have induced a humoral response and reduced β-amyloid plaque burden [91–94]. While not used preventatively as has been done with infectious diseases, IAVs can vaccinate animals against further disease progression in non-infectious diseases. These findings suggest that there will be future development of inovirus-based vaccines against non-infectious diseases that mitigate the damage done to both animals and humans.

Despite the advances in the use of IAVs to combat disease, the consistent development of inovirus-based vaccines still faces challenges. Even when inoviruses have been screened with specific antibodies to bear the desired peptide mimotopes, immunization using IAVs does not always produce the expected immune response. Keller et al. in 1993 were unable to induce the production of broadly neutralizing antibodies against Human Immunodeficiency Virus Type-1 (HIV-1) in rabbits despite having screened for the proper mimotopes [66]. Dorcham et al. in 2005 screened a 15-mer RPL using a broadly neutralizing antibody and, using the selected inoviruses, were able to induce antibodies in vaccinated mice. However, the induced antibodies did not exhibit neutralizing activity against HIV-1 [68]. Other RPLs screened against monoclonal and broadly neutralizing antibodies have produced antibodies that do not have neutralizing capabilities [55,70]. In one such case, crystallization of the specific mimotope revealed that the oligopeptide borne by the inovirus was structurally different that the natural antibody epitope [69]. This structural issue is likely at the foundation of many of the issues involving ineffectual inovirus-based vaccines. When IAVs fail, it is probable that the chosen mimotopes poorly resemble the original antibody epitopes and cannot function in the desired fashion, either failing to induce antibodies or inducing of antibodies without neutralizing capabilities.

Despite the efficacy of these inovirus-based vaccines against a variety of infectious and non-infectious diseases, there are still many diseases for which effective vaccines have not been developed using phage display or other methods. For example as discussed above, despite extensive work with inoviruses beginning in 1993 by Keller et al. [66], there has been very little success developing a (HIV-1) vaccine [95]. While four major epitopes on
the HIV-1 envelope gp41 and gp120 glycoproteins have been identified [96–98], inducing the production of effective antibodies has not been successful [70]. While current techniques have not succeeded, both humoral and cellular responses to HIV-1 through inovirus-based vaccines are being researched [99,100]. However, the groundwork for future work involving HIV-1 and other diseases has been laid out, paving the way for a multitude of various new inovirus-based vaccines.

While there have been many vaccine studies targeting HIV-1 using IAVs, none have been completely successful. Studies involving inovirus-based vaccines targeting HIV-1 initially only used the broadly neutralizing monoclonal antibodies 2F5, 2G12, and b12 [55,66–70]. However, as discussed above, these studies have either failed to induce antibodies or induced non-neutralizing antibodies, despite often inducing a humoral response. In other studies, polyclonal sera from HIV-1-infected individuals have been used to screen RPLs to search for a humoral response. In studies, polyclonal sera from HIV-1-infected individuals have been used to screen RPLs to search for new broadly neutralizing monoclonal anti-HIV-1 antibodies [71–75,101]. These studies have used IAVs to induce the protection of neutralizing antibodies in mice [73] and macaques (against Simian-Human Immunodeficiency Virus) [75]. Inovirus-based vaccines targeting HIV-1 have been able to control viral load in a variety of non-human mammals after a challenge by HIV-1 or induce neutralizing antibodies, but not inhibit novel infection or induce broadly neutralizing antibodies. Additionally, inovirus-based HIV-1 vaccines have often failed due to the autoreactivity of the monoclonal antibodies that can hopefully be avoided with the new ‘next generation’ broadly neutralizing antibodies [102–106].

4. Conclusion

Inoviral vectors have been used extensively in the development of vaccines against a variety of infectious and non-infectious diseases over the past two decades. As shown above, the IAVs have successfully induced a humoral or cellular response, or both. In the studies, the vaccines could provide partial or complete protection against pathogens causing infectious disease or merely lower the burden of infection. Against non-infectious diseases, inovirus-based vaccines have been shown to be effective at mitigating disease development by initiating productive immune responses. There have already been many applications of vaccines against infectious and non-infectious diseases using inoviral vectors and IAVs have distinct characteristics that make them more applicable for the development of new vaccines than other viral vectors.

5. Expert opinion

Inoviruses and by extent IAVs are highly immunogenic and do not require adjuvants, facilitating the ease and simplicity of usage as vaccines. They can display multiple (from few to thousands) copies of a peptide on their surface while still maintaining the desired structure and conformation as well as infectivity with their bacterial hosts. IAVs, by displaying only particular peptides, allow the immune system to interact with a specific epitope rather than a larger, more complex protein, yielding a more targeted response. They are capable of stimulating humoral and cellular immune responses and do not pose known health risks to animals or humans. IAVs can be administered safely in high doses through multiple routes, enhancing their usage in a variety of contexts [107]. With their cost-efficient production, structural simplicity, and record of success in a variety of contexts, IAVs have the potential to be exploited for many new vaccines in humans and animals against a variety of diseases.

Advances in inovirus research and phage display technology are making the development of new vaccines for a variety of diseases feasible in the near future. Currently, there are many diseases without vaccines or for which treatment is highly invasive. Further development involving IAVs will be likely to introduce more, better, and increasingly cost-effective vaccines. As the structure and tools for genetic manipulation of inoviruses are being better developed, IAVs will likely begin to be more extensively introduced into animal and human use. The current research is only revealing the tip of the iceberg of the extensive ways in which inovirus-based vaccines will be applied in future use. Accordingly, there are aspects of the genetic engineering of phage-display that need to be further expanded. Specifically, further studies should be conducted to evaluate the maximum antigenic load capacity of the gp8 coat protein without jeopardizing the architectural integrity and infectivity of the IAV (Ff.g8, see Figure 1). Furthermore, additional research about the potential of using the other capsid proteins (gp3, gp6, gp7, and gp9) or combinations of any of the capsid proteins for antigen display is needed. Additionally, future studies could elucidate the nuances of the uses of individual capsid proteins for specialized applications such as antigen display, penetration, targeting, etc. An additional aspect of IAVs that needs to be further explored is how antigenic display on the surface of IAVs induces immunogenicity. This predictive work needs to be undertaken by experimental and computational (in silico) research.

Further research will involve the development of new vaccines and improving the efficacy of current vaccines. Additional undertakings should be done into identifying the structure of the viruses, since this will better be able to inform how the phage-display technology will best be applied as more complex work is being done using monoclonal and polyclonal antibodies to create more nuanced vaccines. The future has a dual focus: the development of vaccines for infectious diseases and the induction of immune responses in non-infectious diseases to limit the harm that they do (or eliminate them).

The underlying principle of future IAV-based vaccine development could be based on the unique natural symbiosis, which is known to exist between humans, non-pathogenic bacteria such as E. coli, and inoviruses. It is well established that humans or other warm-blooded animals acquire E.coli, including F+ strains, during their first few days in life or even before birth and that they are never thereafter without it. F-specific inoviruses (Ff inoviruses) cannot infect humans, but they propagate at high viral loads in specific strains of E. coli including non-pathogenic strains which are symbiotic to humans. Future IAV-based vaccines within the next five to ten years could take advantage of the triple symbiotic nature between humans, enteric F + E. coli strains and F+-specific
inoviruses to target the induction of mucosal immunity. This approach will be particularly effective against sexually transmitted pathogens such as HIV-1.

Much future study lies the further development of IAVs and how they can induce immune responses on a broad scale. Research regarding the development and advantages of phage display technology was recently recognized by the Nobel Committee. George P. Smith and Gregory P. Winter were awarded the Nobel Prize in Chemistry 2018 for the ‘elegant method known as phage display, where a bacteriophage – a virus that infects bacteria – can be used to evolve new proteins … [This revolution … is bringing and will bring the greatest benefit to humankind’ [108]. The development of more and better inovirus-based vaccines will continue to advance preventative treatment against diseases which have not been able to be combatted.

Acknowledgments

We thank the University of Cyprus for its support.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

ORCID

Zachariah Stern http://orcid.org/0000-0001-9777-4560
Dora C. Stylianou http://orcid.org/0000-0003-4167-1380
Leondios G. Kostrikis http://orcid.org/0000-0002-5340-7109

References

Papers of special note have been highlighted as either of interest (+) or of considerable interest (+) to readers.

1. Twort FW. An investigation on the nature of ultra-microscopic viruses. Lancet. 1915;186(4184):1241–1243.
2. d’Hérelle F. Sur un microbe invisible antagoniste des bacilles dysentériques [On an invisible microbe antagonist of dysentery bacilli]. CR Acad Sci Ser D. 1917;165:373–375.
3. Aghebati-Maleki L, Bakhshinejad B, Baradaran B, et al. Phage display as a promising approach for vaccine development. J Biomed Sci. 2016;23(1):66.
4. Henry KA, Arbabi-Gahroudi M, Scott JK. Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold. Front Microbiol. 2015;6:755.

• A review of novel future applications of phage-display technology

5. Day LA. Inoviruses. In: Mahy BWJ, Regenmortel MHVV, editors. Encyclopedia of virology. Third ed. Oxford: Academic Press; 2008. p. 117–124.
6. Marvin DA, Symmons MF, Straus SK. Structure and assembly of filamentous bacteriophages. Prog Biophys Mol Biol. 2014;114 (2):80–122.
7. Day LA, Marzec CJ, Reisberg SA, et al. DNA packing in filamentous bacteriophages. Ann Rev Biophys Biophys Chem. 1988;17:509–539.
8. Brown LR, Dowell CE. Replication of coliphage M-13. I. Effects on host cells after synchronized infection. J Virol. 1968;2(11):1290–1295.
9. Marvin DA, Hohn B. Filamentous bacterial viruses. Bacteriol Rev. 1969;33(2):172–209.
10. Rakonjac J, Bennett NJ, Spagnuolo J, et al. Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr Issues Mol Biol. 2011;13(2):51–76.

• A recent comprehensive review about the molecular biology and life cycle of FF viruses (F*-specific filamentous viruses)
11. Rakonjac J, Russel M, Khanum S, et al. Filamentous Phage: structure and Biology. Adv Exp Med Biol. 2017;1053:1–20.
12. Beck E, Sommer R, Auerswald EA, et al. Nucleotide sequence of bacteriophage fd DNA. Nucleic Acids Res. 1978;5(12):4495–4503.
13. Hill DF, Petersen GB. Nucleotide sequence of bacteriophage f1 DNA. J Virol. 1982;44(1):32–46.
14. van Wezenbeek PM, Hulsebos TJ, Schoenmakers JG. Nucleotide sequence of the filamentous bacteriophage M13 DNA genome: comparison with phage fd. Gene. 1980;111(1–2):129–148.
15. Russel M, Model P. Genetic analysis of the filamentous bacteriophage packaging signal and of the proteins that interact with it. J Virol. 1989;63(8):3284–3295.
16. Dotto GP, Enea V, Zinder ND. Functional analysis of bacteriophage f1 intergenic region. Virology. 1981;114(2):463–473.
17. Bauer M, Smith GP. Filamentous phage morphogenetic signal sequence and orientation of DNA in the virion and gene-V protein complex. Virology. 1988;167(1):166–175.
18. Shen CK, Ikoku A, Hearst JE. A specific DNA orientation in the filamentous bacteriophage fd as probed by psoralen crosslinking and electron microscopy. J Mol Biol. 1979;127(2):163–175.
19. Lopez J, Webster RE. Morphogenesis of filamentous bacteriophage f1: orientation of extrusion and production of polyphage. Virology. 1983;127(1):177–193.
20. Webster RE, Grant RA, Hamilton LA. Orientation of the DNA in the filamentous bacteriophage f1. J Mol Biol. 1981;152(2):357–374.
21. Caspar DL, Makowski L. The symmetries of filamentous phage particles. J Mol Biol. 1981;145(3):611–617.
22. Stubbs G, Kendall A. Helical viruses. Adv Exp Med Biol. 2012;726:631–658.
23. Glucksmann MJ, Bhattacharjee S, Makowski L. Three-dimensional structure of a cloning vector. X-ray diffraction studies of filamentous bacteriophage M13 at 7 A resolution. J Mol Biol. 1992;226 (2):455–470.
24. Armstrong J, Hewitt JA, Perham RN. Chemical modification of the coat protein in bacteriophage fd and orientation of the virion during assembly and disassembly. Embo J. 1983;2 (10):1641–1646.
25. Smilowitz H. Bacteriophage f1 infection: fate of the parental major coat protein. J Virol. 1974;13(1):94–99.
26. Trenkner E, Bonhoeffer F, Gierer A. The fate of the protein component of bacteriophage fd during infection. Biochem Biophys Res Commun. 1967;28(6):932–939.
27. Chang CN, Blobel G, Model P. Detection of prokaryotic signal peptidase in an Escherichia coli membrane fraction: endopeptidolytic cleavage of nascent f1 pre-coat protein. Proc Natl Acad Sci U S A. 1978;75(1):361–365.
28. Kuhn A, Wickner W. Isolation of mutants in M13 coat protein that affect its synthesis, processing, and assembly into phage. J Biol Chem. 1985;260(29):15907–15913.
29. Kuhn A, Wickner W. Conserved residues of the leader peptide are essential for cleavage by leader peptidase. J Biol Chem. 1985;260 (29):15914–15918.
30. Rakonjac J, Feng J, Model P. Filamentous phage are released from the bacterial membrane by a two-step mechanism involving a short C-terminal fragment of pilE. J Mol Biol. 1999;289(5):1253–1265.
31. Hassapis KA, Stylianou DC, Kostrikis LG. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based
vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. Viruses. 2014;6(12):5047–5076.

**A detailed review of the architecture of inoviruses and major inovirus-associated vectors (IAVs) and related vaccines**

32. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993;217:228–257.

33. Smith GP, Petrenko VA. Phage Display. Chem Rev. 1997;97(2):391–410.

**An early overview of the phage-display and its applications**

34. Chastean L, Ayris J, Pavlik P, et al. Eliminating helper phage from phage display. Nucleic Acids Res. 2006;34(21):e145.

35. Fransen M, Van Veldhoven PP, Subramani S. Identification of peroxisomal proteins by using M13 phage protein VI phage display: molecular evidence that mammalian peroxisomes contain a 2,4-dienoyl-CoA reductase. Biochem J. 1999;340(Pt 2):561–568.

36. Hufton SE, Moerkerk PT, Meulemans EV, et al. Phage display of cDNA repertoires: the pVII display system and its applications for the selection of immunogenic ligands. J Immunol Methods. 1999;231(1–2):39–51.

37. Jespers LS, Messens JH, De Keyser A, et al. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene 36. Hufton SE, Moerkerk PT, Meulemans EV, et al. Phage display of cDNA repertoires: the pVII display system and its applications for the selection of immunogenic ligands. J Immunol Methods. 1999;231(1–2):39–51.

38. Kwasnikowski P, Kristensen P, Markiewicz WT. Multivalent display systems on filamentous bacteriophage pVII minor coat protein. J Immunol Methods. 2005;307(1–2):135–143.

39. Ploss M, Kuhn A. Membrane insertion and assembly of epitope-tagged gp9 at the tip of the M13 phage. BMC Microbiol. 2011;11:211.

40. Lo Passo C, Romeo A, Pernice I, et al. Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization. J Immunol. 2007;178(7):4417–4423.

41. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv. 2005;23(4):378–382.

42. Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab and pIX as display scaffolds. Methods. 2012;58(4):40–46.

43. Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005;97(12):1663–1670.

44. Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005;97(12):1663–1670.

45. Lo Passo C, Romeo A, Pernice I, et al. Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization. J Immunol. 2007;178(7):4417–4423.

46. Riemer AB, Sponer B, et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies to HIV gp120 in rabbits, but not to the same epitope. AIDS Res Hum Retroviruses. 2007;23(11):1416–1427.

47. Riemer AB, Hantusch B, Sponer B, et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies to HIV gp120 in rabbits, but not to the same epitope. AIDS Res Hum Retroviruses. 2007;23(11):1416–1427.

51. Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine. 2005;23(34):4283–4291.

52. Hartmann C, Muller N, Blaukat A, et al. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene. 2010;29(32):4517–4527.

53. Li W, Ran Y, Li M, et al. Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies. BMC Biotechnol. 2013;13:77.

54. Lo Passo C, Romeo A, Pernice I, et al. Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization. J Immunol. 2007;178(7):4417–4423.

55. Wilkinson RA, Evans JR, Jacobs JM, et al. Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope. AIDS Res Hum Retroviruses. 2007;23(11):1416–1427.

56. Bastien N, Trudel M, Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology. 1997;234(1):118–122.

57. Grabowska AM, Jennings R, Laing P, et al. Immunisation with phage displayed peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology. 2000;269(1):47–53.

58. Yu MW, Scott JK, Fournier A, et al. Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides. Virology. 2000;271(1):182–196.

59. Yang Q, Wang L, Lu DN, et al. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Vaccine. 2005;23(31):4088–4096.

60. Wang G, Sun M, Fang J, et al. Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice. Vaccine. 2006;24(35–36):6065–6073.

61. Manoucheharian K, Diaz-Orea A, Gevorkian G, et al. Recombinant bacteriophage-based multiple epitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol. 2004;99(1–2):11–24.

62. Tang LF, Yi XY, Zeng XF, et al. Schistosoma japonicum: isolation and identification of peptides mimicking ferritin epitopes from phage display library. Acta Biochim Biophys Sin (Shanghai). 2004;36(3):206–210.

63. Wu HW, Hu XM, Wang Y, et al. Protective immunity induced by phage displayed mitochondrial related peptides of Schistosoma japonicum. Acta Trop. 2006;99(2–3):200–207.

64. Villa-Mancera A, Quiroz-Romero H, Correa D, et al. Induction of immunity in sheep to Fasciola hepatica with mimotopes of cathepsin L selected from a phage display library. Parasitology. 2008;135(12):1437–1445.

65. Gu Y, Li J, Zhu X, et al. Trichinella spiralis: characterization of phage-displayed specific epitopes and their protective immunity in BALB/c mice. Exp Parasitol. 2008;118(1):66–74.

66. Keller PM, Arnold BA, Shaw AR, et al. Identification of HIV vaccine candidate peptides by screening random phage peptide libraries. Virology. 1993;193(2):709–716.

67. Zwick MB, Bonnycastle LL, Menendez A, et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol. 2001;75(14):6692–6699.

68. Orlandi K, Dogan I, Blotton N, et al. Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. AIDS Res Hum Retroviruses. 2005;21(1):82–92.

69. Menendez A, Calaresa DA, Stanfield RL, et al. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. Faseb J. 2008;22(5):1380–1392.

70. Palacios-Rodriguez Y, Gazarin T, Huerta L, et al. Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb ZF5. Immunol Lett. 2011;136(1):80–89.

71. Scala G, Chen X, Liu W, et al. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol. 1999;162(10):6155–6161.
72. Palacios-Rodriguez Y, Gazarain T, Rowley M, et al. Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope. J Microbiol Methods. 2007;68(2):225–235.

73. Humbert M, Antoni S, Brill B, et al. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progresor plasma. Eur J Immunol. 2007;37(2):501–515.

74. Gazarain KG, Palacios-Rodriguez Y, Gazarain TG, et al. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features. Mol Immunol. 2013;54(2):148–156.

75. Chen X, Scala G, Quinto I, et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med. 2001;7(11):1225–1231.

76. Pedroza-Roldan C, Charles-Nino C, Saavedra R, et al. Variable epitope library-based vaccines: shooting moving targets. Mol Immunol. 2009;47(2–3):270–282.

77. Charles-Nino C, Pedroza-Roldan C, Viveros M, et al. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine. 2011;29(32):5313–5321.

78. Folgori A, Taft R, Meola A, et al. A general strategy to identify mimotopes of pathognomonic antibodies using only random peptide libraries and human sera. Embo J. 1994;13(9):2236–2243.

79. Wan Y, Wu Y, Bian J, et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine. 2001;19(20–22):2918–2923.

80. Lidqvist M, Nilsson O, Holmgren J, et al. Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies. J Immunol Methods. 2008;337(2):88–96.

81. Houimel M, Dellagi K. Peptide mimotopes of rabies virus glycoprotein with immunogenic activity. Vaccine. 2000;19(34):4638–4655.

82. de la Cruz VF, Lal AA, McCutchan TF. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J Biol Chem. 1988;263(9):4318–4322.

83. Greenwood J, Willis AE, Perham RN. Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from plasmodium falciparum circumsporozoite protein as antigens. J Mol Biol. 1991;220(4):821–827.

84. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics.Curr Opin Chem Biol. 2001;5(3):314–324.

85. Henry KA, Murira A, van Houten NE, et al. Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen. Bioengineered Bugs. 2011;2(5):275–283.

86. De Berardinis P, Sartorius R, Fanutti C, et al. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat Biotechnol. 2000;18(8):873–876.

87. Morales J, Martinez JJ, Manoucheharian K, et al. Inexpensive anticysticercosis vaccine: s3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine. 2008;26(23):2899–2905.

88. Fang J, Wang G, Yang Q, et al. The potential of phage display vehicles expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine. 2005;23(40):4860–4866.

89. Wu Y, Wan Y, Bian J, et al. Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anticancer immunity in murine p815 model. Int J Cancer J Inter Du Cancer. 2002;98(5):748–753.

90. Murgas P, Bustamante N, Araya N, et al. A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer. Cancer Immunol Immunother. 2018;67(2):183–193.

91. Solomon B. Active immunization against Alzheimer’s beta-amyloid peptide using phage display technology. Vaccine. 2007;25(16):3053–3056.

92. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer’s beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000;97(21):11455–11459.

93. Frenkel D, Dewachter I, Van Leuven F, et al. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer’s disease by EFRH-phage immunization. Vaccine. 2003;21(10–12):1060–1065.

94. Lavié V, Becker M, Cohen-Kupiec R, et al. EFRH-phage immunization of Alzheimer’s disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci. 2004;24(1):105–113.

95. Hassapis KA, Kostrikis LG. HIV-1 vaccine strategies utilizing viral vectors including antigen-displayed inoviral vectors. Curr HIV Res. 2013;11(8):610–622.

96. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev. 2013;254(1):225–244.

97. Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–1204.

98. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13(9):693–701.

99. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473(7348):523–527.

100. Hansen SG, Piatak M Jr., Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature. 2013;502(7469):100–104.

101. Humbert M, Rasmussen RA, Ong H, et al. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PloS One. 2008;3(12):e3937.

102. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730):1906–1908.

103. Alam SM, McAdams M, Boren D, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2FS and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol. 2007;178(7):4424–4435.

104. Sánchez-Martínez S, Lorizate M, Hermann K, et al. Specific phospholipid recognition by human immunodeficiency virus type-1-neutralizing anti-gp41 2FS antibody. FEBS Lett. 2006;580(9):2395–2399.

105. Scanlan CN, Pantophlet R, Woldmar MR, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–2 mannose residues on the outer face of gp120. J Virol. 2002;76(14):7306–7321.

106. Haynes BF, Moody MA, Verkoczy L, et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies. 2005;14(3–4):59–67.

107. Samoylova TI, Braden TD, Spencer JA, et al. Immunococonception: filamentous bacteriophage as a platform for vaccine development. Curr Med Chem. 2017;24(35):3907–3920.

108. The Nobel Prize in chemistry 2018 NobelPrize.org: Nobel Media AB; 2018 [cited 2019 Jun 10]. Available from: https://www.nobelprize.org/prizes/chemistry/2018/press-release/